Anavasi Diagnostics Revenue and Competitors

We are experienced scientists, engineers, and business people working together to tackle a global challenge: detecting infection with COVID-19. Together, we are determined to help save lives by delivering rapid, precise, and inexpensive diagnostic tests. Our goal is to enable health care professionals to confidently provide lab-quality results in minutes instead of days so that patients can confidently know almost immediately whether they are positive -- or not. Our first product, the AscencioDx™ molecular detection platform, is now in clinical testing* and is designed to provide a precise diagnosis of COVID-19 in under 30-minutes (on average) instead of the 1-3 days that most testing services and physician offices now require for PCR testing. Using our patent-pending proprietary technologies, the AscencioDx diagnostic test is administered painlessly, in just seconds, with a lower-nasal swab. Our mission is to continue developing and marketing diagnostic test systems for diseases in addition to COVID-19 using our PCR- equivalent point-of-care diagnostic platform without the unnecessary delay, expense, or reliance on less-than-precise antigen testing. This is only the beginning. *The AscencioDx molecular diagnostic platform is not currently FDA-approved via 510(k) nor does it have Emergency Use Authorization (EUA). Anavasi Diagnostics makes no claims about the performance of the device until such time as FDA authorization or clearance is achieved. The AscencioDx is not currently for sale.